<DOC>
	<DOC>NCT00839800</DOC>
	<brief_summary>The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy</brief_summary>
	<brief_title>Study to Investigate the Efficacy of Symbicort® SMART.</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<criteria>Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration. Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to baseline for all patients 1530 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks. Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks. Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Symbicort Turbuhaler</keyword>
</DOC>